Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07782684
Recruiting Observational

Reconstruction Kinetics of γδ T Cells After Unrelated Cord Blood Transplantation

NCT07782684 · tracked via the Priya Life Science China tracker
Sponsor
Anhui Provincial Hospital
Phase
Observational
Started
2025-10-09
Last updated
2026-08-24

Condition(s) studied

Hematologic Disease and Disorders

Investigational drug(s) / intervention(s)

Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders

Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders: Allogeneic umbilical cord blood transplantation as a standard treatment for underlying hematological diseases.

Study summary

The primary objective is to investigate the correlation between specific patterns of γδ T cell reconstitution after umbilical cord blood transplantation and key clinical outcomes.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * 1: Patients undergo their first unrelated cord blood transplantation (UCBT) at our institution. 2: Diagnosis of a hematologic malignancy or disorder eligible for UCBT (e.g., acute leukemia, myelodysplastic syndrome, severe aplastic anemia) 3: Willing and able to provide written informed consent. 4: No restrictions on gender, age, or race. Exclusion Criteria: * Participation in an interventional clinical trial investigating prophylactic donor-derived cell infusion (e.g., DLI, MSC) during the study period.

Primary outcome measure(s)

  • Reconstitution level of γδ T cells — 1 year
    The reconstitution level of γδ T cells in peripheral blood will be measured by flow cytometry at 1, 2, 3, 6, 9, and 12 months after umbilical cord blood transplantation. The outcome is measured as the absolute cell count per microliter of blood and/or the percentage of γδ T cells within total lymphocytes.

Trial sites (1)

FacilityCityRegionStatus
the First Affiliated Hospital of University of Science and Technology of China Hefei Anhui Recruiting

More Anhui Provincial Hospital trials in China

The Addictive Diagnostic Value of Apparent Diffusion Coefficients to bpMRI in the Diagnosis of Prostate Cancer Recruiting
Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases Recruiting
A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR) Recruiting
Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor Recruiting
Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07782684 on ClinicalTrials.gov ↗ ← All trials in China